Sugi Predict

Sugi Predict / Compounds / SCHEMBL5226448

SCHEMBL5226448

SCHEMBL5226448

O=C(Nc1ccc(Cl)cc1)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.78
▸ GAA P10253 3/20 0.69
▸ SMN1; SMN2 Q16637 2/20 0.69
▸ HTT P42858 2/20 0.69
▸ NCOA1 Q15788 1/20 0.69
▸ NCOA3 Q9Y6Q9 1/20 0.69
▸ MEN1 O00255 3/20 0.67
▸ KMT2A Q03164 3/20 0.67
▸ CYP1A2 P05177 1/20 0.62
▸ CYP3A4 P08684 1/20 0.62
▸ CYP2D6 P10635 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ ALDH1A1 P00352 5/20 0.62
▸ RAB9A P51151 3/20 0.60
▸ THRB P10828 1/20 0.60
▸ LMNA P02545 2/20 0.60
▸ GLA P06280 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30236947 1.00 MAPT (0.78) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL995085 0.87 GAA (0.77) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL2060528 0.87 CRHBP (0.62) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL4958300 0.86 GAA (0.71) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL4958310 0.86 GAA (0.71) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL94829 0.86 GAA (0.71) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL27657640 0.86 GAA (0.71) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL6814805 0.85 GAA (0.69) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL1010241 0.85 GAA (0.69) MAPTGAASMN1; SMN2HTTNCOA1
SCHEMBL6591721 0.85 P2RX1 (0.64) MAPTSMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103130696-B Anthranilamide compound as well as preparation method and application thereof UNIV SHANDONG 2014-06-11 — — CN claimed
CN-103130696-A Anthranilamide compound as well as preparation method and application thereof UNIV SHANDONG 2013-06-05 — — CN claimed
CN-111646908-B Method for preparing aromatic amine compound 宜昌尚诺德生物医药科技有限公司 2023-03-10 — — CN disclosed
CN-111732493-B Synthesis process of arylamine compound 宜昌尚诺德生物医药科技有限公司 2023-01-24 — — CN disclosed
CN-111732493-A Synthesis process of arylamine compound 宜昌尚诺德生物医药科技有限公司 2020-10-02 — — CN disclosed
CN-111646908-A Method for preparing aromatic amine compound 宜昌尚诺德生物医药科技有限公司 2020-09-11 — — CN disclosed
CN-106800493-B Method for reducing aromatic nitro group into aromatic amine 宜昌尚诺德生物医药科技有限公司 2020-06-30 — — CN disclosed
CN-103130696-B Anthranilamide compound as well as preparation method and application thereof UNIV SHANDONG 2014-06-11 — — CN disclosed
CN-103130696-A Anthranilamide compound as well as preparation method and application thereof UNIV SHANDONG 2013-06-05 — — CN disclosed
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 — — EP disclosed
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ 2006-04-06 — — US disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 — — US disclosed
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors ALTMANN KARL-HEINZ (CH) 2003-04-03 — — US disclosed
US-6448277-B2 ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS NOVARTIS AG (CH) 2002-09-10 — — US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 — — US disclosed
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-02-14 — — US disclosed
CN-1331680-A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-01-16 — — CN disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 — — US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 — — EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064992-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, NR2E3 MAPT 3932/4885GAA 3455/4885SMN1; SMN2 2782/4885
US-20060074112-A1 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NR2E3, AXL, FLT1 MAPT 3569/4885GAA 3746/4885SMN1; SMN2 2644/4885
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 MAPT 4291/4885GAA 77/4885SMN1; SMN2 2752/4885
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, KDR MAPT 3833/4885GAA 3029/4885SMN1; SMN2 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.